Vilon Dosage, half-life & reference guide
Also known as Lys-Glu · KE dipeptide · Lysylglutamic acid
Reviewed Evidence: EmergingPublished by PepVault
A two-amino-acid peptide (Lys-Glu) from the Russian bioregulator program and one of the active parts of the thymus extract Thymalin. In lab studies it switched silenced genes back on in lymphocytes from old people, and in old rats it raised sexual function; small Russian studies in people with type 1 diabetes, with no placebo group, report calmer blood clotting and less insulin needed.
- How often
- Daily
- Half-life
- Unknown
- Evidence
- ●
●●Emerging - Routes
- SubQ, Oral capsules
No controlled study has set a dose of Vilon: the amounts people run are their own protocol, not a reference.
How it works.
A dipeptide, Lys-Glu (KE), from Vladimir Khavinson's St. Petersburg bioregulator program and one of the active parts of the thymus extract Thymalin; Russian papers call it thymomimetic, a peptide that acts like the thymus on the immune system. In lymphocytes from old people grown in the lab it loosened tightly packed chromatin, which its developers read as switching silenced genes back on, and in old male rats it raised sexual function and lowered prolactin. In people with type 1 diabetes, small Russian studies with no placebo group report calmer blood clotting and, in most, less insulin needed. Almost all of the research is by its developers.
Commonly reported: Little to feel during a short course; it is often run beside Epitalon.

Where Vilon works.

Immune system
In the lab. Russian papers call it thymomimetic, a peptide that acts like the thymus on the immune system.
Appetite & metabolism
In people. In people with type 1 diabetes, small Russian studies with no placebo group report calmer blood clotting and, in most, less insulin needed.
An area lights for what a peptide is used for and what people report, with the evidence beside it. It isn’t a promise that it works there.
Week by week.
What to expect in the first 8 weeks
- Onset
- Not established (no controlled timing data)
- Peak effect
- Not established
- Duration
- Courses of 5–10 days (community practice)
Day 1–10Community
A short pulse, not a daily habit
Vilon is run in short courses of about a week, then left for months. Commonly reported: little to feel during the course; some notice mild soreness where it goes in, or an unsettled stomach with capsules.
Updated Nov 2026
Day 10–60Clinical
Where its human studies looked
Vilon's human studies are in type 1 diabetes, and they measured blood: calmer clotting markers and, in most patients, less insulin needed. If you track glucose, the weeks after a course are a reasonable time to look, and worth raising with your clinician if you use insulin.
The science
Kuznik 2006: in type 1 diabetes, Vilon (Lys-Glu) added to treatment significantly reduced or removed signs of chronic DIC (clotting activation), with less effect in elderly patients with severe disease. Kuznik 2007: antithrombin III and protein C rose, fibrinolysis was stimulated, and in most cases the insulin dose needed fell. Neither had a placebo group.
Sources- Kuznik et al. (2006)
- Kuznik et al. (2007)
Updated Nov 2026
Any dayAnimal
What Vilon is built on
A dipeptide from the Russian bioregulator program and one of the active parts of the thymus extract Thymalin. In lymphocytes from old people it switched silenced genes back on, and in old rats it raised sexual function; its human studies are small Russian ones without a placebo group.
The science
KE and EW are active substances of Thymalin (Linkova 2023). Lezhava 2004: in cultured lymphocytes from old people, Vilon unrolled facultative heterochromatin and reactivated ribosomal genes, without touching pericentromeric heterochromatin. Kudriavtseva 2006: in old hemigonadectomized male rats, regular Vilon activated sexual function and lowered prolactin, LH and ACTH changed. Kuznik 2006 and 2007: type 1 diabetes, no placebo group.
Sources- Linkova et al. (2023)
- Lezhava et al. (2004)
- Kudriavtseva et al. (2006)
- Kuznik et al. (2006)
- Kuznik et al. (2007)
Updated Nov 2026
With EpitalonCommunity
The thymus and pineal pair
Vilon is often run beside Epitalon, the thymus peptide with the pineal one, echoing the long Russian study that gave the thymus and pineal extracts together. No study has tested Vilon with Epitalon.
The science
The pairing is community and protocol practice. Its root is Khavinson and Morozov 2003, where the thymus extract Thymalin with the pineal extract Epithalamin reported the largest drop in deaths among 266 older adults followed 6–8 years, against a control group; Vilon is one of Thymalin's active parts (Linkova 2023).
Sources- Khavinson et al. (2003)
- Linkova et al. (2023)
Updated Nov 2026
With ThymalinCommunity
Already inside Thymalin
Vilon is one of the active parts of Thymalin, so running both doubles up on the same dipeptide. No study has tested the pair.
The science
KE (Vilon) and EW (Thymogen) are active substances of Thymalin (Linkova 2023).
Sources- Linkova et al. (2023)
Updated Nov 2026
Day 1 is the day you start it.
No placebo-controlled study of Vilon exists. Timelines are what users commonly report; the mechanism comes from lab studies of human cells and from rats, and the human data are small Russian studies with no placebo group.
Preliminary research
A typical run.
Run notes
- Cycle
- Run in short courses rather than continuously, like the other bioregulators: community courses run about 5–10 days, a few times a year. No study has tested a course length.Community practice — opinions vary. Not a clinical recommendation.
- Timing
- No timing has been studied.
- Routes
- SubQ injection, Oral capsules
- Stacks
- Epitalon, Thymalin
Safety.
Common side effects
- Injection-site discomfort
- Mild stomach upset (capsules)
Interactions
No interaction studies exist. In a Russian study of people with type 1 diabetes, most needed less insulin while on Vilon, so insulin and other glucose-lowering medicines are worth raising with your clinician, as are blood thinners, since the same studies measured changes in clotting.
Safety notes
No study has looked at the safety of Vilon on its own, and its long-term effects are unknown. Discuss with your clinician before use, particularly during pregnancy or breastfeeding, with an autoimmune condition, or with diabetes treated with insulin.
One question at a time.
Compared with.
Questions people ask.
What is Vilon?
A two-amino-acid peptide (Lys-Glu) from the Russian bioregulator program and one of the active parts of the thymus extract Thymalin. In lab studies it switched silenced genes back on in lymphocytes from old people, and in old rats it raised sexual function; small Russian studies in people with type 1 diabetes, with no placebo group, report calmer blood clotting and less insulin needed.
How is Vilon dosed in research?
The library carries no reference dose for Vilon. No controlled study has set a dose of Vilon: the amounts people run are their own protocol, not a reference.
How long does Vilon last?
The half-life of Vilon is unknown (never measured).
What do people report on Vilon?
Commonly reported on Vilon: little to feel during a short course; it is often run beside Epitalon.
Is Vilon safe?
The research basis for Vilon is emerging: primarily preclinical / limited human data. Common side effects in the library: injection-site discomfort and mild stomach upset (capsules).
What does Vilon stack with?
Common stacks for Vilon: Epitalon and Thymalin.
Research.
Reference.
- Cadence
Daily
- Half-life
Unknown
Unknown (never measured)
- Research basis
●
●●EmergingPrimarily preclinical / limited human data
Reviewed How we check the library
